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1. INTRODUCTION
Thalassemia  is  a  common  condition,  particularly  in  the 
meditermean region and southeast Asia.  The term ‘thalassemia’ is used 
to describe a disorder with a siginificant decrease in the synthesis of one 
or more globin chains.1 
     Thalassemia  is  the  most  common  single  gene  disorder  in  the 
world. Thalassemia has an autosomal recessive pattern of inheritance. It 
arises from mutation or deletion in one or more globin gene(s), leading 
to varying degrees of anemia that can range from insignificance to life 
threatening event.2  
Life  long  red  cell  transfusion  remains  the  main  treatment  for 
thalassemia.  The recommended treatment for beta-thalassemia major is 
regular  blood  transfusion  every  three  to  four  weeks,  with  a  goal  to 
correct anemia, to significantly suppress the hyperactive erythropoiesis 
and to inhibit gastrointestinal iron absorption3. The use of regular blood 
transfusion and iron chelation therapy has led thalassemia major from 
fatal  disease  in  early  childhood  to  a  chronic  illness  with  prolonged 
survival .4
Regular blood transfusion regimen is confronted with numerous 
complications.  In  almost  every  patient,  the  transfusion  requirement 
slowly  increases  over  years.  Various  factors  contribute  towards  this 
6
increased  requirement  include:  development  of  hypersplenism, 
alloimmunisation  against  various  blood  group  antigens,  chronic 
infections, folate deficiency, aplastic crisis etc.3
Alloimmunisation  to  red  cell  antigens  and  transfusion 
transmissible  infections  are  the  major  complications  of  transfusion 
particularly those who are chronically transfused. Some alloantibodies 
are hemolytic and may cause hemolytic transfusion reaction and may 
limit  the  possibility  of  further  safe  and  effective  transfusion,  while 
others are clinically insignificant. Alloantibodies must be identified in 
the patient’s serum before each transfusion so that compatible blood can 
be provided. The causes of alloimmunisation are not fully understood, 
however  studies  suggests  that  the  recipients  immune  status,  the 
difference in red cell phenotype between the donor and the recipient, the 
number of units the patients receive are the main contributing factors.1
It  is  a  common  scenario  in  India;  thalassemia  major  patients 
receive suboptimal transfusion and chelation therapy due to number of 
reasons like, financial and social causes, lack of specialized centers, lack 
of  safe  blood  transfusion  services  across  the  country.  There  are  no 
adequate studies published on the adequacy of transfusion,  morbidity 
and survival in thalassemia patients.
The center in which this study was conducted is one of the few 
centers  in  the  country  providing  comprehensive  management  for 
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transfusion  dependent  thalassemia  patients  on  a  day  care  basis.  This 
study is designed to determine the prevalence of alloimmunisation in 
multiply transfused thalassemia major patients and the factors that might 
contribute to their development.
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2. AIMS AND OBJECTIVES
To study the prevalence of alloimmunisation to red cell antigens 
in multiply transfused thalassemia major patients.
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3. REVIEW OF LITERATURE
Thomas Cooley, a Detroit pediatrician described a severe type of 
anemia in Italian children. He noted abundant nucleated red blood cells 
(RBCs) in peripheral blood about which he initially thought was 
erythroblastic anemia. Riette described Italian children with unexplained 
mild hypochromic microcytic anemia. Wintrobe and co-workers in 
United States reported a mild anemia in both parents of child with 
Cooley anemia. This anemia was similar to the one that Riette described 
in Italy. The severe form was labeled as thalassemia major and the mild 
form as thalassemia minor. The term Mediterranean anemia, which 
Whipple introduced, is misleading because this condition can be found 
in any part of the world.5
Thalassemias are inherited disorders of hemoglobin synthesis that 
result from an alteration in the globin chain production. A decrease in 
the production of certain globin chain(s) impedes hemoglobin synthesis 
and  creates  an  imbalance  with  the  other  normally  produced  globin 
chains. This imbalance is the hallmark of all forms of thalassemia. For 
this  reason,  most  thalassemias  are  not  considered  as 
hemoglobinopathies, because the globin chains are normal in structure 
and  the  defect  is  limited  to  a  decreased  production  of  these  normal 
chains.5
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Table 1 Human Hemoglobins6
Embryonic 
Hemoglobins
Fetal Hemoglobins Adult Hemoglobins
Gower1
Zeta(2)
epsilon(2)
HemoglobinF
alpha(2)
gamma(2)
HemoglobinA
alpha(2)
beta(2)
Gower2
alpha(2)
epsilon(2)
HemoglobinA2
alpha(2)
delta(2)
Portland
Zeta(2)
gamma(2)
The type of  thalassemia  usually  carries  the  name of  the  under 
produced chain or chains. The reduction varies from slight decrease to a 
complete absence of production of these chains, Since β chain synthesis 
replaces γ chain synthesis during the first half of first year of life, severe 
forms of  β thalassemia commonly present during the first year.
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Table 2 Classification of β- Thalassemia7
Clinical 
Nomenclature
Genotype Disease
Thalassemia major
Homozygous – βº 
Thalassemia(βº/βº)
Homozygous – 
β+thalassemia(β+/β+)
Severe; requires blood 
transfusion
Thalassemia 
intermedia
βº/β
(β+/β+)
Severe, but does not 
require regular blood 
transfusions
Thalassemia minor
βº/β
β+/β
Asymptomatic with mild 
or absent anemia; red 
cell abnormalities seen
 β – thalassemia is classified as in Table 3.2 above.
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3.1 GEOGRAPHICAL DISTRIBUTION
Figure 1 The  geographic  distribution  of  thalassemia  and  other 
hemoglobinopathies
Thalassemia was originally thought to be a disease limited to the 
Mediterranean region; however it is now known that it occurs widely 
throughout many parts of the world. Thalassemia has been identified 
across southern Europe from Portugal to Spain, Italy and Greece, as well 
as in a number of central European countries and parts of the former 
Soviet Union. Thalassemia also affects the Middle East through to Iran, 
Pakistan, India, Bangladesh, Thailand, Malaysia, Indonesia and southern 
China, as well as countries along the north coast of Africa and in South 
America.8
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Population migration and intermarriage between different ethnic 
groups has introduced thalassemia in almost every country of the world, 
including northern Europe where thalassemia did not previously exist 
and where now it is becoming a major public health problem.8
3.2 THALASSEMIA IN INDIA
In India it is estimated that  thalassemia has a frequency at birth  
of 1: 2700, which means about 9000 cases of thalassemia major are born 
every year.9
The highest frequency of thalassemia trait is reported in Assam,  
North  eastern  India,  and  Gujarat,  followed  by  Sindh,  Punjab,  Tamil 
Nadu, and Maharashtra.2
3.3 GENETICS AND INHERITANCE
Figure 2 Inheritance of thalassemia genes
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When  both  parents  are  carriers,  then  each  child  born  to  these 
parents has a one-in-four (25%) chance of being healthy (without the 
thalassemia gene), a one-in-two chance (50%) of being a carrier like its 
parents,  and  a  one-in-four  chance  (25%)  of  having  ß-thalassemia 
major.10
3.4 PATHOPHYSIOLOGY
The  defect  in  -thalassemia  is  in  the  switch  from gamma  to  
chain production with consequent precipitation of unpaired alpha chains 
in the developing red cells. This appears to be responsible for premature 
cell death in the bone marrow and hence for ineffective erythropoiesis 
and also for the abnormal red cells in the peripheral blood that are the 
cause of  hypersplenism.  In  the bone marrow the myeloid :  erythroid 
ratio is reversed and studies show an arrest of maturation in the early 
polychromatic erythroblasts.11
The effect of ineffective erythropoiesis on growth is generally seen in 
early childhood, and is quite different from the endocrine growth failure 
that occurs in older iron loaded patients. Early failure of growth occurs 
only in association with a grossly overactive marrow, when the 
transfusion scheme is too low, or when there is compensatory bone 
marrow expansion in the presence of hypersplenism.11
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3.5 AGE AND SYMPTOMS OF PRESENTATION
Age at onset of symptoms varies significantly. In thalassemia severe 
cases are evident at birth, unexplained hypochromasia and microcytosis 
in a neonate are highly suggestive of the diagnosis. However in severe 
forms of β-thalassemia, symptoms may not be evident until the second 
half of the first year of life. Till that time the production of gamma 
globins and their incorporation into fetal hemoglobin can mask the 
condition.5
In reviewing 121 patients, Modell and Berdouckas, found that 60% 
presented within the first year: the mean age of presentation was 6 
months.12
Table 3 Age at presentation of beta thalassemia
Age (years) Thalassemia major
< 1yr 75 (62%)
1-2yrs 35 (29%)
>2yrs 11 (9%)
Total 121
Both  sexes  are  equally  affected  in  thalassemia.   Thalassemia 
should  be  considered  in  any  children  with  hypochromic  microcytic 
anemia that does not respond to iron supplementation. The physician 
should  always  inquire  about  the  patients  ethnic  back ground,  family 
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history of hematological disorders, and dietary history.5
Occasionaly in children aged below 5 years, the condition may 
not be recognized because of the delay in cessation of HbF production. 
The  affected  children  are  usually  pale,  with  feeding  problems, 
irritability, recurrent infections, diarrhoea, and progressive enlargement 
of abdomen due to hepato splenomegaly.5
The  bony  changes  may  be  severe  resulting  in  a  characteristic 
radiologic  picture.  The  skull  is  large  and  deformed  by  frontal  and 
posterior bossing. The zygomatic bones are prominent, the base of nose 
appears depressed and pneumatization of the sinuses are delayed.  Over 
growth  of  the  maxilla  produces  malocclusion.   Metatarsal  and 
metacarpal bones are the first to expand as a consequence of increased 
erythropoiesis. Poor growth is due to multiple factors, and it can be seen 
patients with well controlled disease and uncontrolled disease.11
The stigmata of severe untreated β-thalassemia major include.10
• severe anemia with hemoglobin level of 3-7g/dl
• Massive splenomegaly
• Severe growth retardation
• Bony abnormalities
3.6 LABORATORY  DIAGNOSIS  OF  B-THALASSEMIA 
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MAJOR 13, 14
• Anemia is severe with hemoglobin – 2-3g/dl
• Hematocrit and RBC counts are also decreased
• MCV,MCH,MCHC are all decreased
• Red cell Distribution width (RDW)- increased
• RBC histogram is shifted to the right and abnormal in shape
Figure 3 Peripheral blood smear in beta thalassemia major
• RBC’s are markedly hypochromic, microcytic with aniso and 
poikilocytes.
• Target cells are many with schiztocytes leptocytes. (Large flat 
cells).
• Moderate basophilic stippling is seen.
• Platelet count is usually normal, unless the spleen is markedly 
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enlarged.
• Nucleated red blood cells are always seen.
• Reticulocyte count – relative increase 5-10%.
Bone marrow findings and iron status
• Bone marrow–erythroid, hyperplasia with dyserythropoiesis
• Stainable iron is increased and ring sideroblast may be seen.
• Serum iron- increased/ normal
• TIBC – decreased/normal
• Ferritin – increased/normal
Hemoglobin Electrophoresis
• HbA – decreased
• HbF – increased
• HbA2- variable.
3.7 BLOOD TRANSFUSION SUPPORT
Patients with thalassemia major require medical treatment and a 
regular blood transfusion. Children with hemoglobin values below 6–7 
gm/dl  should  be  observed  very  carefully  at  regular  intervals  with 
particular respect to their activity, growth and development, spleen size 
and early  skeletal  changes.  Any infant  showing deleterious  effect  of 
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anemia of this kind will require transfusion. Blood transfusion should be 
initiated at an early age when the child is symptomatic, after an initial 
period  of  observation  to  assess  whether  the  child  can  maintain  an 
acceptable level of hemoglobin without transfusion.15
Chronic  regular  blood transfusions  provide  patients  with many 
benefits  including  revival  of  complication  of  anemia,  elimination  of 
ineffective erythropoiesis and its complications, allowance of normal or 
near  normal  growth  and  development  and extension  of  patient’s  life 
span.11
Several  blood  transfusion  regimens  have  been  introduced.  The 
regimen that attempts to maintain a pretransfusion hemoglobin level of 
9-9.5g/dl seems more practical, less demanding and more cost effective 
than others .15
Thalassemia  patients  who  are  planned  for  chronic  transfusions 
require  a  pretransfusion  work  up  which  should  include  red  cell-
phenotype, hepatitis B vaccination and hepatitis work up, iron and folate 
levels should also be measured.
Transfused blood should preferably be leukocyte poor, which are 
transfused at 10-15ml/kg at the rate of 5ml/kg/hr every 3-5 weeks. Some 
patients  with  very  low  pretransfusion  hemoglobin  may  benefit  from 
repeat  transfusion on the following day.  Patients with repeated Febrile 
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non-hemolytic  transfusion  reaction  (FNHTRs)  may  benefit  from 
premedication with acetaminophen and diphenhydramine hydrochloride 
before  each  transfusion.  Some  patients  require  saline  washed  or 
deglycerolized  RBCs.10 After  many  years  of  monitoring  transfused 
patients, the inadequacy of transfusion alone as a therapy became clear, 
and  the  accumulation  of  iron  from the  transfused  blood  was  slowly 
recognized.  Today  regular  blood  transfusion  with  well-monitored 
chelation therapy has become the standard therapy and has drastically 
changed the outlook of these populations of patients.
3.8 COMPLICATIONS OF BLOOD TRANSFUSION
Thalassemia patients are prone to develop complications due to 
chronic blood transfusion. The major complications of blood transfusion 
mainly divided into immunological and non-immunological.
Immunological 
Complications
Non - Immunological 
Complications
Others
Transfusion
transmitted 
infection
Circulatory overload
Hypocalcemia
Iron overload
Cardiac
Endocrine
Growth retardation
Hypersplenism
Bone changes
Thromboembolism
 FNHTR
Urticarial reaction
Alloimmunisation
Hemolytic transfusion 
reaction
TAGVHD
TRALI
Post transfusion purpura
Immunomodulation
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3.8 RED CELL ALLOIMMUNIZATION
Red cell antibodies are detectable in up to 2.6% of the general 
population,  at  higher  rates  among  individuals  who  are  chronically 
transfused,  and  rarely  among  infants  younger  than  4  months. The 
prevalence among different patient groups varies from 18% to 47% in 
patients  with  sickle  cell  anemia,  5%  to  11%  in  patients  with 
thalassemia.16 
The risk of red cell antibody formation depends on a myriad of 
factors including the patient’s underlying illness, genetic predisposition, 
immune  status,  degree  and  duration  of  antigen  exposure  (e.g.,  total 
number of transfusions), and degree of antigen disparity with the blood 
donor.17
Delayed  hemolytic  transfusion  reactions  due  to  non-ABO 
incompatibility  are  largely  prevented  with  accurate  antibody 
identification and component phenotyping during compatibility testing. 
However, recently transfused red cells may become incompatible if red 
cell antibodies quickly develop because of transfusion in a previously 
sensitized  patient  (anamnestic  response).  Despite  the  coincidence  of 
antigen  positive  transfused  red  cells  and  incompatible  antibody, 
investigation  often  reveals  no  evidence  of  accelerated  red  cell 
destruction;  in  these  cases,  the  findings  have been termed a  delayed 
serologic transfusion reaction (DSTR).18
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The diagnosis of a DHTR requires clinical or laboratory evidence 
that  the  newly  discovered  red  cell  alloantibody  is  actually  causing 
hemolysis (e.g., fever, falling hematocrit, and jaundice). 
Implicated  antibodies  in  DHTRs  are  typically  IgG,  reactive  at 
370C  that  fix  complement  (C3d)  on  red  cells,  antibodies  to  various 
antigens of the Rh, kell, Kidd and Duffy (Fya) system are more likely to 
cause delayed hemolytic reactions than other antibody specificities. The 
progressive removal of portions of the red cell membrane by phagocytic 
cells  in  the  spleen  results  in  the  appearance  of  spherocytes  in  the 
peripheral circulation. Accelerated destruction of transfused red cells is 
also  evident  by  reticulocytosis,  unconjugated  hyperbilirubinemia,  and 
increased serum lactate dehydrogenase. Prolonged intervals between the 
initial and subsequent red cell transfusion predispose to DHTRs because 
the  antibody  titer  may  decrease  so  that  it  is  no  longer  detectable  in 
routine  pretransfusion  screening  tests.  Delayed  hemolytic  transfusion 
reactions occur 2 days to 2 weeks after re-exposure to the implicated 
antigen and are associated with mild hemolysis of transfused red cells in 
most clinical settings.17
Bystander  hemolysis  of  the  patient’s  own red  cells  as  well  as 
transfused  red  cells  may  result  from  complement  activation  and 
deposition of C3d on autologous red cells.
Standard blood bank practices are designed to prevent DHTRs by 
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accurate record keeping of prior red cell alloantibodies and avoidance of 
re-exposure to implicated red cell antigens for all future transfusions. As 
a further precaution in repeatedly and chronically transfused patients, 
investigation  should  include  obtaining  an  accurate  patient  history 
regarding previous transfusions at other institutions and any clinically 
significant serologic findings. Primary red cell alloimmunisation may be 
prevented by avoiding unnecessary transfusion and by minimizing the 
potential  for  blood  group  antigen  incompatibility  between  the  blood 
donor and transfusion recipient.17 Because patients with thalassemia  are 
at the greatest risk of serious transfusion complications and are often 
dependent  on  long-term red  cell  transfusion,  additional  measures  are 
warranted  to  prevent  red  cell  alloimmunisation  and  prevent  DHTRs. 
Recent  clinical  practice  guidelines  advocate  that  all  patients  with 
thalassemia  major and sickle cell disease, should have their extended 
red cell antigen phenotype (ABO, Rh, Kell,  Kidd, Duffy, Lewis, and 
MNSs blood group systems)  determined before  they start  transfusion 
therapy, and they should receive ABO / Rh type-specific units that are 
phenotypically  matched  for  C,  E,  and  K1.19 More  extensive  antigen 
matching  is  recommended  for  those  patients  who  develop  red  cell 
alloantibodies.
3.9 TRANSFUSION TRANSMISSIBLE INFECTIONS
Transfusion Transmissible Infections (TTI) like hepatitis B virus 
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(HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) 
etc, are dreaded complications of transfusion.20
The risks of infectious disease transmission by transfusion were 
reduced through introduction and progressive improvements  in donor 
screening  and  infectious  disease  testing.16 The  discovery  in  the  mid 
1980’s  that  acquired  immunodeficiency  syndrome  (AIDS)  could  be 
transmitted  by  transfusion,  heightened  public  concern  about  blood 
safety. Over the past decade efforts have been made to quantify the risk 
of transfusion transmitted infectious disease.20
In India it is mandatory to screen donated blood for, HBsAg, anti 
HIV 1&2 (since 1991), anti HCV (since 2000), syphilis and malaria 
The  greatest  threat  to  the  safety  of  the  blood  supply  is  the 
donation of blood by seronegative donors during the infectious window 
period when the donors are undergoing seroconversion. 20
In  addition  to  the  above,  other  viruses  like  Cytomegalovirus 
(CMV), Epstein-Barr virus, Human Herpes-6, Human Herpes-7, Human 
Herpes-8,  are  associated  with  leukocyte  contamination  during 
transfusion.  The human T-cell  leukemia/lymphoma virus (types 1&2) 
targets.
 T-lymphocytes  and  are  solely  transmitted  through  cellular 
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products.  Primary  toxoplasmosis  has  been  reported  to  be  transmitted 
through whole blood. Variant Creutzfeldt- Jacob disease (vCJD), SEN 
virus, west Nile virus, TT virus are recently feared to be transmitted by 
transfusions.21 Yersinia  enterocolitica  is  increasingly  recognized  as  a 
cause  of  morbidity  and  mortality  in  patients  with  iron  overload 
especially those with homozygous beta-thalassemia. 22
The seroconversion rates  among these donors were highest  for 
HBV (9.80) 100, 0000 person years, followed by HCV (4.32 per 100, 
0000), HIV (3.37 per 100,000), and HTLV (1.12 per 100,000). These 
rates  are  lower  than  those  in  the  general  population,  a  finding  that 
confirm  the  effectiveness  of  donor  education  and  history  taking 
procedures.20
Implementation  of  nucleic  acid  testing  (NAT)  will  reduce  the 
residual risk of HIV by 50% and the risks HCV and HBV infection can 
be expected to be reduced by 72 and 42 percent respectively .Although 
new techniques of testing will  bring the goal close to zero risk,  it  is 
unlikely  that  any  test  or  combination  of  tests  will  be  100  percent 
effective in detecting window period infections. It is also important to 
recognize that new, direct viral detection tests will supplement existing 
screening  assays  rather  than  to  replace  them.20  The  levels  of  virus 
decline  after  seroconversion,  a  small  percentage  of  antibody positive 
donors will test negative for viral antigens and nucleic acids yet still be 
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infectious.  Therefore  the  yield  and  cost  effectiveness  of  new,  direct 
assays  for  viral  detection  is  low  and  decisions  about  their 
implementation will be difficult.20
3.10 OTHER COMPLICATION
As  the  risks  of  infectious  disease  transmission  by  transfusion 
were reduced through the introduction of progressive improvement in 
donor  screening,  non  infectious  complications  although  uncommon, 
now account for most of the significant morbidity and mortality from 
blood  transfusion  in  developed  countries.16    Non  infectious 
complications  now  far  exceed  the  risk  of  human  immunodeficiency 
virus or other infectious diseases by order of magnitude.  Iron induced 
heart failure and arrhythmias are the most common causes of death in 
patients with thalassemia major accounting for 70% of death.23
Iron chelating agents like desferrioxamine and deferiprone were 
used  for  two  decades.  The  newly  synthetic  iron  chelator  deferasirox 
(ICL-670, Exjade) is  currently  used for  iron chelation in thalassemic 
patients.  Deferasirox  is  given  in  once  daily  dose  of  20  mg/kg  body 
weight. The drug is well tolerated and is highly selective for iron and 
does  not  induce  the  excretion  of  zinc  or  copper.  Iron  excretion  is 
predominantly fecal.23
Endocrine  complications  are  mostly  due  to  iron  overload  and 
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deposition of iron in organs and tissues. Patients with thalassemia major 
frequently inhabit features of diabetes mellitus due to iron deposition in 
the pancreas.21 Growth retardation is caused in part by the diversion of 
caloric resources for erythropoiesis as well as by chronic anemia. Hyper 
transfusion usually restores normal growth, but unless chelation therapy 
is initiated in early life, these patients rarely grow normally. Excessive 
chelation  with  DFO  may  also  cause  growth  retardation.  Impaired 
Growth  hormone  production  or  deficiency  of  somatomedin  by  the 
hemosiderotic  liver  is  the  direct  cause  of  growth  retardation. 
Involvement of the adrenal and thyroid glands also contribute to growth 
failure.24   
Adult  patients  with  thalassemia  major  are  known  have  low 
fertility  due  to  hypogonodotrophic  hypogonadism.  Both  primary  and 
secondary sexual characteristics are usually delayed in both males and 
females.
Females  are  frequently  oligomenorrhic  and  amenorrhoeic 
Pregnancy  complications  seen  are  frequently  due  to  endocrine  and 
cardiac  complications.  However  case  reports  have  demonstrated 
successful pregnancy and delivery of healthy babies.5 Early intervention 
with  adequate  transfusion  support  along  with  iron  chelation  and 
hormonal therapy prevents permanent damage and preserve fertility.24,21
3.11 ROLE OF SPLENECTOMY 
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The constant bombardment of the reticuloendothelial system with 
abnormal  red  cells  and  development  of  the  extramedullary 
erythropoiesis  are  the  important  causes  of  Splenomegaly. 
Alloimmunisation and autoimmunisation to red cell antigens also causes 
splenomegaly. Patients present with physical discomfort because of the 
enlarged  spleen.  Several  studies  have  reported  a  decreased  red  cell 
survival in thalassemic children with enlarged spleen.25
               Large spleen is associated with inadequate rise in post 
transfusion hemoglobin and increased blood consumption there by to 
iron over load. Splenectomy is considered when
1) Transfusion  requirement  exceeds   200-220  ml/kg/year,  to  
maintain a pretransfusion hemoglobin of about 10 
gm/dl
2) Leucopenia
3) Thrombocytopenia
4) A very large spleen with a possibility of splenic rupture.5,26
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3.12 DIET
A normal diet is recommended with small doses folic acid, ascorbic 
acid, and alphatocopherol (vitE) is sufficient. Iron supplements should not 
be given, and foods rich in iron should be avoided. Drinking coffee or tea 
with food has been shown to decrease iron absorption from gut.5
3.13 HEMATOPOIETIC STEM CELL TRANSPLANTATION
Hematopoietic  stem  cell  transplantation  (HSCT)  is  the  only 
recommended curative treatment for thalassemia major. Care givers of 
patients  with  thalassemia  are  frequently  confronted  with  a  choice 
between  standard  therapy  and  HSCT.  The  15yr  cardiac  disease  free 
survival rate for patients receiving standard therapy exceeds 90% and is 
similar for those without risk factors who have under gone HSCT.5 
Even though blood transfusion is not required after a successful 
transplant, certain individuals may need continued chelation therapy to 
remove excessive iron. The optimal time to start  such treatment,  is a 
year  after  the  successful  HSCT.  Long  term  outcome  for  transplant, 
including fertility is not known. The cost of long term standard therapy 
is  known to be higher than the cost  of  transplant.  The possibility  of 
developing cancer is not known.5
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3.14 NEWER THERAPIES
Induction  of  fetal  hemoglobin  synthesis  by  drugs  like,  5-
azacytidine  which  can  reduce  the  severity  of  beta-thalassemia  by 
improving the imbalance between alpha and non alpha globins are under 
clinical trials.27 The possibility of correction of the molecular defect in 
hematopoietic stem cell by transfer of normal gene via a suitable vector 
or  by  homologous  recombination  is  being  actively  investigated.  The 
most  promising  results  in  mouse  model  have  been  obtained  with 
lentiviral vectors.28
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4. PATIENTS AND METHODS
This prospective study was conducted over one year period from 
2007-2008 at Voluntary Health Services Hospital, Tharamani, Chennai 
on 51 registered Thalassemia Major patients. The study was approved 
by  the  Ethical  committee,  The  Tamil  Nadu  Dr.M.G.R.  Medical 
University.  Written  consent  from  patients  was  also  obtained. 
Thalassemia major patients treated with ten or more transfusions were 
included  in  the  study.  Diagnosis  of  thalassemia  was  confirmed  by 
standard Hb electrophoresis.
Clinical  transfusion record of patients who fulfilled the criteria 
were collected and entered in the proforma, with special reference to age 
,age at the time of diagnosis, frequency of transfusion ,present clinical 
status,  any  increase  in  transfusion  requirements,  ethnicity,  status  of 
spleen, TTI screening ,iron chelation allo antibody screen etc.
 Blood samples were obtained for  the detection of  anti  red cell 
alloantibodies.  Serum was  separated  using  was  standard  blood  bank 
method  and  stored  in  labeled  tubes  at  -20ْ  C,  till  the  tests  were 
performed in batches.
32
4.1 INCLUSION CRITERIA
1. Registered  patients  of  thalassemia  major  confirmed  by  the 
Hemoglobin electrophoresis.
2. Patients  who  had  at  least  ten  transfusions  before  the 
commencement of study.
3. Patients who were on regular transfusion regimen.
4. Patients who were willing to participate in the study by giving 
written consent.
4.2 EXCLUSION CRITERIA
1. Patients other than thalassemia major like thalassemia minor 
and  intermedia  and  all  other  variants  of 
thalassemia.
2. Patients who were not under regular transfusion regimen.
4.3 MATERIALS AND METHODS
• Screening cells
• Test Tubes
• Anti Human Globulin (AHG)
• LISS
• 22% BSA
• Dry air incubator
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• Micropipette
• Disposable tips
               Antibody screening is done by conventional tube technique 
using 22% bovine serum albumin, and low ionic strength saline (LISS) 
as enhancement reagents. A three cell panel from Dia-Med was used for 
antibody screening.
4.4 SALINE INDIRECT ANTI GLOBULIN TEST
1. Add 2drops of serum to properly labeled tubes.
2. Add 1 drop of 2-5% saline suspended reagent cells to each 
tube and mix.
3. Centrifuge  and  observe  for  hemolysis  and  agglutination. 
Grade and read the results.
4. Incubate  at  37ْ  C for  30  min,  centrifuge  and  observe  for 
hemolysis and agglutination. Grade and record the results.
5. Wash the cells three times with saline and completely decant 
the final wash 
6. Add a drop of AHG (Anti Human Globulin) to the dry cell 
button and mix well centrifuge and observe for agglutination. 
Grade and record the results
7. Confirm the  validity  of  the  negative  tests  by  adding  IgG 
coated red cells
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4.5 ALBUMIN OR LISS-ADDITIVE INDIRECT ANTIGLOBIN 
TEST 
1. Add 2 drops of serum to properly labeled tubes.
2. Add equal  volume of 22% bovine albumin or LISS additive.
3. Add 1drop of 2-5 % saline suspended reagent  cells  to each 
tube and mix
4. For  albumin  incubate  at  37ْ  C   for  30minutes,  for  LISS 
incubate for 15 minutes
5. Centrifuge and observe for hemolysis and agglutination. Grade 
and record the results. Follow steps 5,6,and 7 as in the earlier 
procedure
4.6 INTERPRETATION OF RESULTS
The results were interpreted as positive or negative based on the 
presence  or  absence  of  agglutination.  Both  positive  and  negative 
reactions  were  important  in  antibody  identification.  Positive  reaction 
was  compared  to  the  antigen  pattern  expressed  by  the  panel  cells 
.Negative  reactions  are  also  important  as  they  allowed  tentative 
exclusions on non-reactive cells.
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4.7 EXCLUSION OR CROSSING OUT
The first  approach to the interpretation of  panel  results  was to 
exclude specificities based on non-reactivity with the serum tested. Such 
a system is sometimes referred to as a “cross-out” or “rule-out” method. 
Once results had been recorded on the worksheet, the antigen profile of 
the first non-reactive cell was examined. If an antigen was present on 
the cell and the serum did not react, the presence of the corresponding 
antibody could be at least tentatively ruled out. After all antigens present 
on that cell had been crossed off, interpretation proceeded with the other 
non-reactive cells and additional specificities were excluded.
Next,  the  cells  reactive  with  the  serum  were  evaluated.  The 
pattern of reactivity of the non-excluded specificity was compared to the 
pattern of reactivity obtained with the test serum. If there was a pattern 
that matched exactly, that was most likely the specificity of the antibody 
in the serum however, if there were remaining specificities that had not 
been  excluded,  additional  testing  was  needed  to  eliminate  remaining 
possibilities  and  to  confirm  the  specificity  identified.  This  requires 
testing the serum against additional cells.
Once  tentative  identification  had  been  established,  testing  the 
serum against  cells  selected  for  specific  antigenic  characteristic  gave 
more information than using an additional, unmodified panel. When the 
exclusion  approach  identified  simple  antibody  specificities,  it  was 
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considered  only  a  provisional  step,  particularly  if  the  cross-out 
completed  was  based  on  non-reactivity  of  cells  with  heterozygous 
expression of an antigen.
Figure 4 Antibody screening three –cell panel
Figure 5 Antibody Identification 11 –cell panel
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5. RESULTS 
A  total  of  51  thalassemia  major  patients  undergoing  regular 
transfusion therapy were analysed as follows :
5.1 DEMOGRAPHIC DETAILS
• Age distribution 
• Gender distribution
• Ethnicity
• Distribution of blood group.
5.2 CLINICAL FEATURES
5.3 ANALYSIS OF TRANSFUSION 
• Age at diagnosis and start of first blood transfusion
• Transfusion interval.
• Transfusion reactions
• Transfusion transmissible infections
• Status of spleen.
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5.1 DEMOGRAPHIC DETAILS 
Table 4 Age Distribution of the Study Group
Age group
in years
Number of 
patients
Percent %
< 5 11 21.6
6 – 10 22 43.1
11 – 15 8 15.7
16 – 20 7 13.7
21 – 25 1 2.0
25 – 30 2 3.9
TOTAL 51 100.0
40
22%
42%
16%
14%
2% 4%
<5
6-10
11-15
16-20
21-25
25-30
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Table 5 Gender Distribution of the Study Group
Sex Number of Patients Percent %
Male 26.0 51.0
Female 25.0 49.0
Total 51.0 100.0
51%
49%
Male 
Female 
From the above table 51% of the patients were male and 49% of 
the study patients were female.  There was no gender difference in the 
distribution of the disease.
The majority of the patients fall between the age group 6 – 10 
years.  The mean age of the study group is 9.84 years.
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Table 6 Ethnicity of the Study Group
Ethnicity Frequency Percent %
Tamil Nadu 48 94.1
 Maharashtra 2 3.9
Rajasthan 1 2.0
Total 51 100.0
94%
4% 2%
Tamil Nadu
Maharashtra
Rajasthan
94% of patients in the study group were from Tamil Nadu, two 
patients  (3.9%)  were  from  Maharashtra  and  1  (2%)  patient  from 
Rajasthan.
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Table  7 Distribution Of Blood Group
Blood Group Number of 
Patients Percent %
O Positive 23 45.1
O Negative 0 0
B Positive 15 29.4
B Negative 02 03.9
A Positive 07 13.7
A Negative 01 02.0
AB Positive 03 05.9
Total 51 100.0
23
15
2
7
1
3
0
5
10
15
20
25
Number of 
Patients
O Postive B Negative A Negative
Blood Group
Most of the study population belongs to O Positive blood group 
(45%)
5.2 CLINICAL FEATURES 
The Thalassemic children presented with the following clinical 
features
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• Growth retardation
• Splenomegaly
• Hypoparathyroidism 
• Hypothyroidism
• Cardiac abnormalities
• Diabetes mellitus
• Clinically stable.
Table 8 Present Clinical Status
Clinical Features Number of patients Percent %
Growth retardation 11 21.5
Splenomegaly 4 7.8
Hypoparathyroidism 2 3.9
Hypothyroidism 2 3.9
Cardiac abnormalities 2 3.9
Diabetes mellitus 2 3.9
Clinically stable 23 45
24%
9%
4%
4%
4%4%
51%
Growth retadation 
Splenomegaly
Hypoparathyroidism
Hypothyroidism
Cardiac abnormalities
Diabetes mellitus
Clinically stable
Analysis of Transfusion 
Thalassemic  children  who  received  regular  transfusion  were 
analysed as follows.
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• Age at Diagnosis and start of first blood transfusion
• Transfusion Interval
• Transfusion Reaction
• Transfusion Transmitted infection
• Splenectomy
Table 9 Age at Diagnosis and Start of First Blood Transfusion
Age in months Number of patients Percent %
< 12 MONTHS 48 94.1
> 12 MONTHS 03 05.9
Total 51 100
94%
6%
<12 Months 
>12 Months 
Majority (94%) presented with clinical symptoms and had their 
first transfusion before one year of age.
Table 10  Transfusion Interval 
Tranfsusion 
frequency in days
Number of 
patients
Percent %
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21 37 72.6
30 13 25.5
35 1 2.0
TOTAL 51 100.0
73%
25%
2%
21 days 
30days 
35days 
The transfusion interval varied widely in the study group ranging 
from 15 days to 35 days.  The mean transfusion interval was 28.6 days. 
Most of the patients (70.6%) had their next transfusion every 21 days.
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Table 11 Transfusion Reactions 
Type of reaction Number of patients Percent %
FNHTR 13 25.5
No Reaction 38 74.5
Total 51 100.0
13
38
0
5
10
15
20
25
30
35
40
FNHTR No Reaction
Type of Reaction
No
. o
f P
at
ie
nt
s 
Febrile  non  Hemolytic  transfusion  reaction  was  only  acute 
transfusion reaction noted in the patients during the study period. Of the 
total  51  patients  studied,  13  had  febrile  non  hemolytic  transfusion 
reaction on one or more occasions. No hemolytic reaction was observed 
during the study period.
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Table 12 Transfusion Transmitted Infections
TTI  Results Number of Patients Percent %
HCV Positive 7 13.7
HIV Positive 1 2.0
Non reactive 43 84.3
7
1
43
HCV Postitive 
HIV Postivie 
Non Reactive 
7 (13.7%) patients had HCV, one had HIV, in total of 51 patients 
studied. None of them had HBV, syphilis or malaria.
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Table 13 Status of spleen
Splenectomy Number of Patients Percent %
Yes 16 31.4
No 35 68.6
Total 51 100.0
0
5
10
15
20
25
30
35
40
Yes No
Splenectomy
No
. o
f p
at
ie
nt
s 
31.4% of the patients were splenectomised before the start of the 
study.
Alloimmunisation 
A  total  of  51  multiply  transfused  thalassemia  patients  were 
studied  in  which  none  of  them  was  found  to  have  developed 
alloantibody to any of the red cell antigens.
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6. DISCUSSION
Alloimmunisation  to  red  cell  antigens  is  one  of  the   major 
complication of chronic blood  transfusion
The causes of alloimmunisation in thalassemia patients are not 
fully  understood.  Various factors  affect  the rate  of  alloimmunisation, 
such as ethnic factors, disparity between antigenic frequency of donors 
and  recipient,  age  at  start  of  first  blood  transfusion,  type  of  blood 
product  used  (leuko reduced or  non-leuko reduced),  number  of  units 
transfused and splenectomy.29
Table 14 The  following  table  shows  the  prevalence  of 
alloimmunisation  among  thalassemia  major  patients  in 
various studies
Study
Number of 
patients
 Percentage  of 
Alloimmunisation
Bibi shahin shamsian 
et al. 2008
121 7.4
Ansari et al. 2008 80 3.75
M.N. Noor Hashina et al. 2006 58 8.6
Khalid Hassan et al. 2004 75 22.7
G. Sirchia et al. 1985 1435 5.2
Present Study 51 0
As  it  is  seen  from  the  table,  the  prevalence  of  red  cell 
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alloimmunisation varies from as low as 3.75% a study by Ansari et al. to 
as high as 22.7% in Pakistan by Khalid et al.30
A  low  rate  of  alloimmunisation  is  attributed  to  homogenicity 
between  the  blood donor  and  the  recipient  population.  Sirchia  et  al. 
showed  a  low  prevalence  of  5%  alloimmunisation  in  presumed 
homogenous population of Greece and Italy. In the present study also 
94% of the patients were homogenous population of Tamil Nadu.31
Rubella  and  model  reported  a  lower  incidence  of 
alloimmunisation (2%) who started their transfusion before 12 months 
as opposed to 15% who started their transfusion after 48 months. In the 
present study 94% of the patients had their first transfusion before 12 
months.
Blumberg  et  al.  found  that  WBC reduction  is  associated  with 
reduced frequency of alloimmunisation which is attributed to reduced 
immune  activation  in  leukodepleted  blood.32 All  the  patients  in  the 
present study received leuko poor blood. 
Floss et al. observed that children do not produce alloantibodies 
and  immunological  mediated  transfusions  are  quite  rare  despite 
exposure  to  many  red  cell  antigens.33 In  the  present  study  also 
alloimmunisation to red cell antigen was not detected. 
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There was no alloantibody identified in a study by Tahhan et al on 
40 Arab multitransfused children.30 The homogeneity between the donor 
and recipient population, the age at which the first transfusion was given 
and the utility of leuko reduced products to all  patients could be the 
reason. 
The high prevalence of TTI in this study i.e. 7 patients (13.7%) 
for HCV and 1 patient (2%) for HIV may be due to reason that some of 
the patients received blood from other centers before registering into the 
present centre, and also possibly due to window period donations.
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7. SUMMARY AND CONCLUSION
 This study was conducted on 51 registered thalassemia major 
patients for the presence of alloantibody to red cell antigens. 
 26 patients were males and 25 of them were females. Majority 
of the patients had maintained a pretransfusion hemoglobin of 
7 – 9.5 gm/dl.
 70% of the study population were below 14 yrs of age. 
 94% of the study population were ethnically identical with the 
donor. 
 All the transfused units were leukocyte reduced. 
 Most of the patients had their transfusion once every 21 days. 
 None of the 51 patients developed alloantibody to any of the 
red cell antigens. 
 Six of the patients had transfusion transmitted hepatitis C virus 
and one patient had HIV virus infection.
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8. LIMITATIONS OF THE STUDY 
1. Only 51 thalassemia major patients were enrolled at the centre 
where this study was undertaken.  The study could be carried 
out on more number of thalassemia major patients. 
2. Antibody  screening  was  done  by  using  conventional  tube 
technique.  The gel technique could be more sensitive. 
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10. APPENDIX 
10.1 THESIS PROFORMA
Name :
Address :
Phone no :
Age : 
Sex :
Age at diagnosis :
Age at starting of Transfusion :
Place of  diagnosis :
Blood Group :
Pre Transfusion Hemoglobin :
Iron Chelation therapy: Yes /no :
Splenectomy: Yes / no :
H/O Transfusion reactions :
RBC alloantibody screen :
Antibody Identification :
i
CONSENT
I confirm that I read and understood the information dated for 
Above research study dated ----------------and I received chance to ask 
the questions.
My participation in this study is voluntary and I know that I am free to 
withdraw from the study at any time, without giving any reason and 
without affecting of my medical care or legal rights.
I  agree not  to  restrict  or  interfere  any data  or  results  those are  used 
properly those are obtained from this study.
I agree to participate in this research study for the above listed purpose.
---------------------------------------
patient’s Name (print)
Age of the patient :----------------
--------------------------------------- --------------------------
--------
Signature  of Parent /guardian Date
------------------------------------------- ----------------------------------
-
Signature of the person who obtains consentDate
-------------------------------------------
Subject ID No.
------------------------------------------
Subject Initials
ii
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{õß ÷{õø¯õÎ uPÁÀ £iÁzøu ¬ÊÁx©õP  £izx, ¦¶¢x öPõsk C¢u B´ÂÀ 
P»¢x öPõÒÍ ¬Ê©Úxhß \®©vUQ÷Óß.
{õß |øÚUS®÷£õx C¢u B´ÂÀ C¸¢x Â»S® _u¢vµ® GÚUS  EÒÍx 
Gß£øu AÔ÷Áß.
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\õm]°ß øPö¯õ¨£® :
J¨¦uÀ ö£Ö£Á¶ß 
øPö¯õ¨£® :
÷uv :
iii
S.
No Name Age / Sex Blood Grp Ethnicaty
Age at Diag., 
start of 1st 
trans.
Transfusion 
Regimen
Frequency
Present 
Clinical
 Status
Transfusio
n 
Reactions
Increased
 Blood Req. Splenectemy
TTI
Results Hb%
Alloantibody 
Scrren
1 Punniasloksamal 6 yrs / M 0 + tamil nad 3 months regularly once 21 days Normal No No No Neg Hb-8.5 g /dl Nil
2 Hemadurga 7 yrs / f B + tamil nad 3 months Regular once 21 days Normal No No No Neg Hb-7 g /dl Nil
3 Jeyavedan 6 yrs /M B + tamil nad 3 months Regular 21 days  No No No Neg Hb-7.5 g /dl Nil
4 Sugan 3 yrs / M B neg tamil nad 3 months Regular 21 days Normal  No No No Neg Hb-8 g /dl Nil
5 Shiva 7 yrs / M A neg tamil nad 6 months Regular 21 days Normal
Frequent 
FNHTR No No HCV + Hb-8.5 g /dl Nil
6 Sandhiya 5 Yrs / F B Pos tamil nad 3 Yrs Regular 21 days Normal No No No neg Hb- 7g /dl Nil
7 Madhu 14 Yrs / M AB Pos tamil nad 6 months Regular one month Growth retard no No At 5 yrs of age neg Hb- 7.6g /dl Nil
8 Sahana 12 Yrs / F B Neg tamil nad 6 months Regular 21 days Growth retard no No No neg Hb- 7g /dl Nil
9 Anaga 13 yrs / F B pos tamil nad 6 months Regular 21 days Normal no No No neg Hb- 7.8 g /dl Nil
10 Fazila Banu 27 yrs / F B Pos tamil nad one year Regular 21 days  No No No HIV + Hb- 8.5 g /dl Nil
11 Suganya 10 yrs / F O Pos tamil nad 6 months Not under regular Normal No NO At 5 yrs of age Neg Hb- 8.5 g /dl Nil
12 Manigandan 6 yrs / M O Pos tamil nad 9 months Regular 21 days splenomegaly no No No Neg Hb- 6.5 g /dl Nil
13 Asharaf 8 yrs / M A pos tamil nad 1  1/2  yrs Regular 21 days Anemia no No No Neg Hb- 6 g /dl Nil
14 Yogeswaran 8 yrs / M O Pos tamil nad 3 months Regular 21 days normal No No No Neg Hb- 7.6g /dl Nil
15 Aneez Nazreen 6 Yrs / F A1B Pos tamil nad 2 yrs Regular 21 days Normal No No No Neg Hb- 8.3 g /dl Nil
16 Sanjay 20 yrs / M O Pos Rajasthan 4 months Regular 21 days
Growth retard 
Cardi abnor No No At 6 Yrs of Age Neg Hb- 7.8 g /dl Nil
17 Aravind Srinivas 18 yrs / M B post tamil nad 3 months Regular 21 days
Growth retard 
cardiac abnor FNHTR + No in 1993 HCV + Hb- 7.5 g /dl Nil
18 Salman 19 yrs / M O Pos tamil nad 6 months Regular 21 days Growth retard FNHTR + No At 6 yrs of Age Neg Hb- 7.5 g /dl Nil
19 Katheeja 6 Yrs / F B post tamil nad 5 Months Regular 21 days Frontal bossing FNHTR + No No Neg Hb- 5 g /dl Nil
20 Asithir one yr / F B Post tamil nad 3 months Regular 21 days Normal No No No Neg Hb- 7.8 g /dl Nil
21 Lawanya Sri 1 1/2 yr / F O Pos tamil nad 5 months Regular one month  No No No Neg Hb- 8.5 g /dl Nil
22 Sathish 19 yrs / M B Pos tamil nad 6 months Regular 21 days
Growth retard 
cardiac abnor No No yes / 11.5.2006 HCV + Hb-7 g /dl Nil
23 Mahalakshmi 6 Yrs / F B Pos tamil nad 6 months Regular 21 days Normal No No No Neg Hb-7 g /dl Nil
24 Rajkumar 3 yrs / M A Pos tamil nad 6 months Regular 21 days Normal No No No Neg Hb-8.5 g /dl Nil
25 Eyal Raj 17 / M B Pos tamil nad 3 years Not regular
Growth retard 
hypoparathyroi
d No No At 10 yrs of age Neg Hb-7.5 g /dl Nil
S.
No Name Age / Sex Blood Grp Ethnicaty
Age at Diag., 
start of 1st 
trans.
Transfusion 
Regimen
Frequency
Present 
Clinical
 Status
Transfusio
n 
Reactions
Increased
 Blood Req. Splenectemy
TTI
Results Hb%
Alloantibody 
Scrren
26 Nikleswaran 9 yrs / M O pos tamil nad 6 months Regular 21 days Normal No No No neg Hb-8 g /dl Nil
27 Krishna 2 yrs / M O pos tamil nad 6 months Regular 21 days Normal No No No neg Hb- 7.5 g /dl Nil
28 Ayyappan 14 yrs / M A pos tamil nad 3 months Regular one month Normal FNHTR  + No At 4 yrs of age HCV + Hb- 8.3 g /dl Nil
29 Vijayalakshmi 25 yrs / F A1 pos tamil nad 3 months Regular 3-4 months
Growth retard 
Diabetis FNHTR  + No At 7 yrs of age  Hb- 6.5 g /dl Nil
30 Paneerselvam 28 yrs / M B pos tamil nad 7 month Regular 21 days 
Hepatomegaly 
Growth retard 
cardiac abnor FNHTR  + No At 5 yrs of age HCV+ Hb-7.5g/dl Nil
31 Thenmozhi 17 yrs / F O pos tamil nad 3 months Regular 6 months
Growth retard 
Hypothyroid  yes yes at 2003 HCV + Hb- 8 g /dl Nil
32 Rahul 9 yrs / M B pos tamil nad 6 months Regular 21 days SPLEEN + FNHTR yes no neg Hb- 6 g /dl Nil
33 Shankari 3 yrs / F B pos tamil nad 3 months Regular one month Normal No No No neg Hb- 8.4 g /dl Nil
34 Banushree 3 yrs/ F O pos tamil nad 9 months Regular one month Normal No No No neg Hb- 8 g /dl Nil
35 Thamirabarani 8 yrs / F O pos tamil nad one year Regular one month Normal FNHTR yest at 2007 neg Hb- 7. g /dl Nil
36 Leema Elizabeth 8 yrs / F A1 pos tamil nad 4 yrs Regular one month Normal No No No neg Hb- 7.8 g /dl Nil
37 Vaishnavi 11 yrs / F O pos tamil nad 2.5  Regular 21 days spleenomegaly No No No neg Hb- 8.2 g /dl Nil
38
Navaneetha 
krishnan 18 yrs /M O pos tamil nad 7 months Regular 21 days
Growth retard 
Diabetis No No at 3  1/2 yrs neg Hb- 6.8 g /dl Nil
39 Sowndarya 7 yrs / F O pos tamil nad 4 yrs Regular one month Normal No No yes / 6.11.2007 neg Hb- 7.6 g /dl Nil
40 Daniel Raj 1 1/2 / M O pos tamil nad 7 months Regular one month Normal No No No neg Hb- 7.4 g /dl Nil
41 Yogeswari 8 yrs / M O pos
Maharastr
a 3 months Regular 21 days Normal No Yes No Neg Hb- 8 g /dl Nil
42 Vignesh 7 yrs / M B pos tamil nad 6 months Regular 21 days Normal No No No neg Hb- 8.4 g /dl Nil
43 Durga 4 yrs / F O pos tamil nad 5 months Regular 21 days Normal No No No Neg Hb- 7.6 g /dl Nil
44 Kavya Shree 2 yrs / F A pos tamil nad 6 months Every 35 days Normal No No No Neg Hb- 7.6 g /dl Nil
45 Sundar Sham 8 yrs / M O pos tamil nad 4 months Regular 30 days Normal No No No neg Hb- 7.2 g /dl Nil
46 Priya 12 yrs / F B pos tamil nad 5 months Regular 21 days Normal No No No neg Hb- 8.2 g /dl Nil
47 Mahesh 8 yrs / M O pos tamil nad 3 months Regular 21 days Normal No FNHTR+ No neg Hb- 7.6 g /dl Nil
48 Jeeva 9 yrs / M B pos tamil nad tamil nad Regular one month  No No No neg Hb- 8.2 g /dl Nil
49 Suba 6 yrs / F AB Pos tamil nad tamil nad Regular 21 days spleenomegaly No No No neg Hb- 6.4 g /dl Nil
50 Kumar 14 yrs / M A Pos tamil nad 3 months Regular one month Growthh retard No No yes at 4 yrs neg Hb- 8 g /dl Nil
51 Alamelu 12 yrs / F O pos tamil nad 4 months Regular 21 days Normal No No yes at 5 yrs neg Hb- 7.2 g /dl Nil
10. i-iii
